MERTK activation drives osimertinib resistance in EGFR-mutant non–small cell lung cancer

MLA

Dan Yan, et al. “MERTK Activation Drives Osimertinib Resistance in EGFR-Mutant Non–small Cell Lung Cancer.” The Journal of Clinical Investigation, vol. 132, no. 15, Aug. 2022. EBSCOhost, https://doi.org/10.1172/JCI150517.

APA

Dan Yan, Justus M. Huelse, Dmitri Kireev, Zikang Tan, Luxiao Chen, Subir Goyal, Xiaodong Wang, Stephen V. Frye, Madhusmita Behera, Frank Schneider, Suresh S. Ramalingam, Taofeek Owonikoko, H. Shelton Earp, Deborah DeRyckere, & Douglas K. Graham. (2022). MERTK activation drives osimertinib resistance in EGFR-mutant non–small cell lung cancer. The Journal of Clinical Investigation, 132(15). https://doi.org/10.1172/JCI150517

Chicago

Dan Yan, Justus M. Huelse, Dmitri Kireev, Zikang Tan, Luxiao Chen, Subir Goyal, Xiaodong Wang, et al. 2022. “MERTK Activation Drives Osimertinib Resistance in EGFR-Mutant Non–small Cell Lung Cancer.” The Journal of Clinical Investigation 132 (15). doi:10.1172/JCI150517.